Actavia Life Sciences's quarterly market cap
declined
from Sep. 2023 ($15.44 Mil) to Dec. 2023 ($5.94 Mil) but then
stayed the same
from Dec. 2023 ($5.94 Mil) to Mar. 2024 ($5.94 Mil).
Actavia Life Sciences's annual market cap
declined
from Sep. 2021 ($4.13 Mil) to Sep. 2022 ($2.20 Mil) but then
increased
from Sep. 2022 ($2.20 Mil) to Sep. 2023 ($15.44 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Actavia Life Sciences's Enterprise Value for Today is $0.69 Mil.
Actavia Life Sciences (OTCPK:RASP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Actavia Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actavia Life Sciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Actavia Life Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Actavia Life Sciences's Market Cap for the fiscal year that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actavia Life Sciences (RASP) has a Market Cap of $0.39 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Market Cap too high?
Actavia Life Sciences' current Market Cap is $0.39 Mil. The Biotechnology industry median Market Cap is 117.63. Actavia Life Sciences' value of $0.39 Mil is 99.7% below this industry median.
How does Actavia Life Sciences' Market Cap compare to BWV and FNCH?
Actavia Life Sciences' Market Cap of $0.39 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 117.63. Actavia Life Sciences' value of $0.39 Mil is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actavia Life Sciences's current Market Cap of $0.39 Mil is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Actavia Life Sciences and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actavia Life Sciences's current Market Cap is $0.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Market Cap of $0.39 Mil. The current Market Cap is $0.39 Mil and 99.7% below the Biotechnology industry median of 117.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Market Cap is $0.39 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RASP has been successfully added to your 